Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis
In the present report, we have described the clinical course of 34 adult patients who had received blinatumomab or inotuzumab ozogamicin for relapsed or refractory acute lymphoblastic leukemia. Both agents induced high rates of molecular complete remission, with manageable toxicity profiles, allowing 80% of transplantable patients to proceed to allogeneic stem cell transplantation. These data suggest high efficacy and safety for both drugs in a bridge-to-transplantation setting.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Patrick Stelmach, Klaus Wethmar, Christoph Groth, Daniela V. Wenge, J örn Albring, Jan-Henrik Mikesch, Christoph Schliemann, Christian Reicherts, Wolfgang E. Berdel, Georg Lenz, Matthias Stelljes Tags: Original Study Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Hematology | Leukemia | Lymphoma | Myeloma | Stem Cell Therapy | Stem Cells | Study | Toxicology | Transplants